Interestingly, differential production of the pro-inflammatory cytokine, IL-17 by CD4− and CD4+ liver iNKT cells has been reported [11], which could explain the superior anti-tumor response of the CD4− subset. This evidence concerns the gene CD4 and neoplasm.